Analysis reveals key interactions with inhibitors in Mycobacterium tuberculosis, suggesting strategies for new treatments.
Tuberculosis (TB) remains a major global threat, demanding new therapeutic strategies. Dihydrofolate reductase (DHFR), essential for cell survival and a known drug target, has emerged as a promising enzyme for anti‐TB drug development. Using crystallographic structures of Mycobacterium tuberculosis DHFR (MtDHFR) complexed with classical and potential inhibitors, a quantum‐chemical analysis was performed through the molecular fractionation with conjugate caps (MFCC) scheme within the density functional theory (DFT) framework to quantify individual amino acid contributions to ligand‐protein interactions. Energetically significant interactions were observed within a 6.0 Å pocket, when convergence of the total interaction energy (TIE) was found. The key residues I5, W6, D19, I20, R23, D27, Q28, H30, F31, R32, L50, K53, L57, R60, I94, and E111 were identified, along with the energetically relevant regions of the ligands and the major secondary structures of the protein. These results may guide the design of new anti‐TB drugs.
No takes yet. Share an insight, caveat, or question.
Neto et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: